Prognostic value of inflammatory markers in predicting recurrence-free survival in gastrointestinal stromal tumor patients: A nomogram-based approach

Table 3 Correlation between preoperative systemic immune-inflammation index, neutrophil/lymphocyte ratio, and clinicopathological parameters, n (%)/mean ± SD

Variable	SII		P value	χ2	NLR		P value	χ2
	< 1079 (n = 82)	≥ 1079 (n = 42)			< 5.79 (n = 90)	≥ 5.79 (n = 34)
Gender			0.920	0.010			0.447	0.577
Male	32 (39.0)	16 (38.1)			33 (36.7)	15 (44.1)
Female	50 (61.0)	26 (61.9)			57 (63.3)	19 (55.9)
Age	56.12 ± 12.796	56.14 ± 12.493	0.968	0.002	56.04 ± 12.556	56.59 ± 13.738	0.807	0.60
BMI	22.13 ± 3.643	22.49 ± 3.819	0.914	0.12	22.35 ± 3.970	22.00 ± 2.863	0.268	1.239
Anatomic site of GIST			0.497	0.460			0.098	2.742
Stomach	52 (63.4)	24 (57.1)			62 (68.9)	18 (52.9)
Non-Stomach	30 (36.6)	18 (42.9)			28 (31.1)	16 (47.1)
Targeted therapy			0.511	0.432			0.816	0.054
Yes	19 (23.2)	12 (28.6)			22 (24.4)	9 (26.5)
No	63 (76.8)	30 (71.4)			68 (75.6)	25 (73.5)
Tumor size, cm	5.88 ± 3.395	7.24 ± 4.057	0.078	3.160	6.15 ± 3.657	6.85 ± 3.723	0.308	1.047
Size of GIST, cm			0.920	0.10			0.111	2.536
< 5 cm	32 (39.0)	16 (38.1)			23 (28.8)	15 (44.1)
≥ 5 cm	50 (61.0)	26 (61.9)			57 (71.3)	19 (55.9)

SII: Systemic immune-inflammation index; NLR: Neutrophil/lymphocyte ratio; GIST: Gastrointestinal stromal tumor; BMI: Body mass index.